Literature DB >> 24300727

Long term outcome of primary urothelial papilloma: a single institution cohort.

Samir Al Bashir1, Asli Yilmaz, Geoffrey Gotto, Kiril Trpkov.   

Abstract

The aim of this study was to investigate the long term outcome of primary urothelial papilloma (UP). We retrieved 41 primary UP, diagnosed between January 2000 and December 2009. Follow-up was obtained by searching pathology and clinical electronic databases. Mean patient age was 57 years (range 30-84 years), with a male-to-female ratio of 1.9:1. Mean follow-up was 81 months (range 3-127 months). In 37 (90.2%) patients, no recurrence and/or progression were documented and no subsequent higher grade neoplasms were diagnosed. Three male patients were diagnosed with UP at 1, 31, and 43 months after the initial resection; the repeat diagnosis of UP at 1 month likely represented an incomplete resection. Thus, only two of 41 patients (4.9%) had a recurrent UP. One of these patients had a subsequent papillary urothelial neoplasm of low malignant potential (PUNLMP), 17 months after the recurrent UP (48 months after the initial UP). Only one additional male had a subsequent PUNLMP, 76 months after the initial UP. Thus, only two of 41 patients (4.9%) had a subsequent PUNLMP, both presenting with haematuria. Primary UP does not progress to UC when diagnosed using strict criteria, when no previous or concurrent neoplasms are documented, and when complete initial resection is performed.

Entities:  

Mesh:

Year:  2014        PMID: 24300727     DOI: 10.1097/PAT.0000000000000029

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  2 in total

1.  Primary papilloma of the proximal ureter in a 13-year old boy: A rare case.

Authors:  Mahtab Rahbar; Keykhosro Mardanpour; Maryam Rahbar; Seyed Javad Nasiri
Journal:  Int J Surg Case Rep       Date:  2020-05-23

2.  Urothelial Papilloma of the Urinary Bladder: A Case Report and Literature Review of a Rare Entity.

Authors:  Ahmed M Abdel Gawad; Ahmed Rabie; Mohammed S Abdelwahed; Abdulkarim Hasan
Journal:  Cureus       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.